The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
Jun. 26, 2012
José Ignacio Andrés-gil, Toledo, ES;
Peter Jacobus Johannes Antonius Buijnsters, Beerse, BE;
Andrés Avelino Trabanco-suárez, Toledo, ES;
Meri DE Angelis, Munich, DE;
Greta Constantia Peter Vanhoof, Beerse, BE;
Jérôme Emile Georges Guillemont, Val de Reuil, FR;
Frederik Jan Rita Rombouts, Beerse, BE;
Maarten Vliegen, Beerse, BE;
Guy Maurits R. Bormans, Leuven, BE;
Sofie Jeanne Leopoldine Celen, Leuven, BE;
José Ignacio Andrés-Gil, Toledo, ES;
Peter Jacobus Johannes Antonius Buijnsters, Beerse, BE;
Andrés Avelino Trabanco-Suárez, Toledo, ES;
Meri De Angelis, Munich, DE;
Greta Constantia Peter Vanhoof, Beerse, BE;
Jérôme Emile Georges Guillemont, Val de Reuil, FR;
Frederik Jan Rita Rombouts, Beerse, BE;
Maarten Vliegen, Beerse, BE;
Guy Maurits R. Bormans, Leuven, BE;
Sofie Jeanne Leopoldine Celen, Leuven, BE;
Janssen Pharmaceutica NV, Beerse, BE;
Abstract
The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.